The Angiotensin Converting Enzyme 2 (ACE2), Gut Microbiota, and Cardiovascular Health

2017 ◽  
Vol 24 (9) ◽  
Author(s):  
Joao Marcus Oliveira Andrade ◽  
Deborah de Farias Lelis ◽  
Valeria Mafra ◽  
Junio Cota
2020 ◽  
Vol 18 (3) ◽  
pp. 261
Author(s):  
NataPratama Hardjo Lugito ◽  
Andree Kurniawan ◽  
Vika Damay ◽  
Henny Chyntya ◽  
Natasya Sugianto

2020 ◽  
Vol 26 (10) ◽  
pp. 1186-1195
Author(s):  
Elena Barengolts ◽  
Emily Daviau Smith

Objective: To review data implicating microbiota influences on Coronavirus Disease 2019 (COVID-19) in patients with diabetes. Methods: Primary literature review included topics: “COVID-19,” “SARS,” “MERS,” “gut micro-biota,” “probiotics,” “immune system,” “ACE2,” and “metformin.” Results: Diabetes was prevalent (~11%) among COVID-19 patients and associated with increased mortality (about 3-fold) compared to patients without diabetes. COVID-19 could be associated with worsening diabetes control and new diabetes diagnosis that could be linked to high expression of angiotensin-converting enzyme 2 (ACE2) receptors (coronavirus point of entry into the host) in the endocrine pancreas. A pre-existing gut microbiota imbalance (dysbiosis) could contribute to COVID-19–related complications in patients with diabetes. The COVID-19 virus was found in fecal samples (~55%), persisted for about 5 weeks, and could be associated with diarrhea, suggesting a role for gut dysbiosis. ACE2 expressed on enterocytes and colonocytes could serve as an alternative route for acquiring COVID-19. Experimental models proposed some probiotics, including Lactobacillus casei, L. plantarum, and L. salivarius, as vectors for delivering or enhancing efficacy of anti-coronavirus vaccines. These Lactobacillus probiotics were also beneficial for diabetes. The potential mechanisms for interconnections between coronavirus, diabetes, and gut microbiota could be related to the immune system, ACE2 pathway, and metformin treatment. There were suggestions but no proof supporting probiotics benefits for COVID-19 infection. Conclusion: The data suggested that the host environment including the gut microbiota could play a role for COVID-19 in patients with diabetes. It is a challenge to the scientific community to investigate the beneficial potential of the gut microbiota for strengthening host defense against coronavirus in patients with diabetes. Abbreviations: ACE2 = angiotensin-converting enzyme 2; ARI = acute respiratory infection; CoV = coronavirus; COVID-19 = Coronavirus Disease 2019; DM = diabetes mellitus; GI = gastrointestinal; HFD = high-fat diet; MERS = Middle East respiratory syndrome; NOD = nucleotide-oligomerization domain; SARS = severe acute respiratory syndrome; T1D = type 1 diabetes mellitus; T2D = type 2 diabetes mellitus


2020 ◽  
Author(s):  
Cristina Garcia-Iriepa ◽  
Cecilia Hognon ◽  
Antonio Francés-Monerris ◽  
Isabel Iriepa ◽  
Tom Miclot ◽  
...  

<div><p>Since the end of 2019, the coronavirus SARS-CoV-2 has caused more than 180,000 deaths all over the world, still lacking a medical treatment despite the concerns of the whole scientific community. Human Angiotensin-Converting Enzyme 2 (ACE2) was recently recognized as the transmembrane protein serving as SARS-CoV-2 entry point into cells, thus constituting the first biomolecular event leading to COVID-19 disease. Here, by means of a state-of-the-art computational approach, we propose a rational evaluation of the molecular mechanisms behind the formation of the complex and of the effects of possible ligands. Moreover, binding free energy between ACE2 and the active Receptor Binding Domain (RBD) of the SARS-CoV-2 spike protein is evaluated quantitatively, assessing the molecular mechanisms at the basis of the recognition and the ligand-induced decreased affinity. These results boost the knowledge on the molecular grounds of the SARS-CoV-2 infection and allow to suggest rationales useful for the subsequent rational molecular design to treat severe COVID-19 cases.</p></div>


Sign in / Sign up

Export Citation Format

Share Document